Dr. Eva Zsigmond, Ph.D.

Dr. Eva Zsigmond, Ph.D.

Assistant Professor, Center for Immunology and Autoimmune Diseases; Director, Transgenic and Stem Cells Service Unit

Email Address: Eva.M.Zsigmond@uth.tmc.edu
Phone Number: 713-500-2453
Room Number: SRB 430C


Dr. Eva Zsigmond is Assistant Professor, Center for Immunology and Autoimmune Diseases and Director of Transgenic and Stem Cell Service Unit at the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases. She received her graduate training at the University of Toronto in Canada. Her doctoral thesis focused on the study of lipoprotein metabolism and the development of atherosclerosis. She commenced her postdoctoral training in the Department of Cell Biology at Baylor College of Medicine in the laboratory of Dr. Lawrence Chan. During her training and later as a junior faculty, she pursued her research interest in genetically altered animal models, and her studies involved the generation of transgenic and knock-out animals to study the genetics of cardiovascular disease.

When Dr. Zsigmond joined the IMM in 1997 she was instrumental in setting up the Laboratory for Developmental Biology. This laboratory was established to function as a core and support facility for investigators whose research requires the generation of transgenic or gene knock-out animal models.

In the past seven years, the facility has produced over five hundred new, genetically-altered mouse models. The Laboratory for Developmental Biology is also the only Stem Cell Core Facility in the Texas Medical Center. In this capacity, the laboratory generates novel mouse stem cell lines and helps scientists apply this technology to their specific research. Dr. Zsigmond directly oversees the operation of these core facilities, and she is also involved in pursuing original research in stem cell biology

The laboratory's recent accomplishments include the derivation of new, highly effective mouse stem cells and the genetic modification of these cells to express Green Fluorescent Protein (GFP). These GFP-labeled stem cells are currently used in studies of stem cell differentiation. Preliminary results show successful differentiation of mouse embryonic stem cells to cardiomyocytes and endothelial cells. Dr. Zsigmond's future research plans are to further develop a research program in stem cell therapy and to apply the experience gained using mouse embryonic stem cells to research with human stem cells.